News
The OIS Index gained 5.2% in April, on the heels of a 4.4% gain in March. Ophthalmic stocks have far outperformed key market benchmarks over…
Read More
The “Masters of the Industry” panel at the recent OIS@ASCRS 2018 in Washington, DC, put into context the impact digital health is having on eye…
Read More
Here are 15 takeaways from last week’s OIS@ASCRS 2018. Barry Cheskin of PowerVision reported on a pilot study of 27 patients who had the FluidVision…
Read More
Within a week Nancy Lurker went from president and CEO of what had been known as an R&D company to the same title at a…
Read More
There are 41 different sessions, panels, and presentations happening at OIS@ASCRS 2018 – including five different breakout sessions on everything from dry eye to emerging…
Read More
The OIS Index gained 4.4% in March, far outperforming its key benchmarks during another volatile month for the markets. The NASDAQ Biotechnology Index declined by…
Read More
Artificial intelligence (AI) is making waves in diagnosing retinal disease. Computers with this technology can be quicker and less expensive than a doctor, but can…
Read More
An emerging gene therapy candidate for the treatment of inherited eye disease has taken a step forward with MeiraGTx announcing that it has received Priority…
Read More
“Everything kind of fits together in a puzzle,” Clearside Biomedical CEO and president Daniel H. White tells OIS Weekly in explaining the company’s recent moves.…
Read More
Over the past decade, the treatment of ocular surface conditions such as dry eye and meibomian gland dysfunction (MGD) has evolved from “pats on the…
Read More
The OIS Index declined by 4.2% in February, tracking stock market benchmarks during a volatile month. The NASDAQ Biotechnology Index suffered a slightly larger decline…
Read More
Apellis Pharmaceuticals‘ plans to begin the Phase III trial of its complement C3 inhibitor candidate APL-2 for treatment of geographic atrophy received a boost last…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")